West Pharmaceutical Services The pharmaceutical delivery components company reported fourth-quarter earnings in February of $18.9 million, or 56 cents a share, up from year-earlier earnings of $5.9 million, or 18 cents. "Management indicated 2012 guidance reflects $0.08-0.15 earnings per share impact from Crystal Zenith products and other proprietary safety/administration devices," Jefferies analysts wrote in a Feb. 23 report. "However, WST acknowledged these sales depend on non- and pre-commercial customer use, which carries a higher risk that revenue may be lower than expected." Forward Annual Dividend Yield: 1.8% Rated "B+ (Buy)" by TheStreet Ratings: The company's fourth-quarter gross profit margin was about the same as it was the previous year. West Pharmaceutical Services has weak liquidity. Its Quick Ratio is 0.98, which demonstrates a lack of ability to meet its short-term cash needs. In the fourth quarter, stockholders' net worth increased 4.66% from the prior year. TheStreet Ratings' price target is $47.64. -- Written by Alexandra Zendrian >To contact the writer of this article, click here: Alexandra Zendrian >To submit a news tip, send an email to: firstname.lastname@example.org. >To follow the writer on Twitter, go to Alexandra Zendrian.